Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma

Alessandra Ferri 1,2, Venturina Stagni 2,3 and Daniela Barilà 1,2,*

1 Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy; alessandraferri4@gmail.com
2 Laboratory of Signal Transduction, IRCCS-Fondazione Santa Lucia, 00179 Rome, Italy; venturina.stagni@cnr.it
3 Institute of Molecular Biology and Pathology, National Research Council (CNR), 00185 Rome, Italy
* Correspondence: daniela.barila@uniroma2.it; Tel.: +39-065-0170-3168

Received: 15 June 2020; Accepted: 9 July 2020; Published: 11 July 2020

Abstract: Glioblastoma multiforme (GBM) is a severe brain tumor whose ability to mutate and adapt to therapies is at the base for the extremely poor survival rate of patients. Despite multiple efforts to develop alternative forms of treatment, advances have been disappointing and GBM remains an arduous tumor to treat. One of the leading causes for its strong resistance is the innate upregulation of DNA repair mechanisms. Since standard therapy consists of a combinatory use of ionizing radiation and alkylating drugs, which both damage DNA, targeting the DNA damage response (DDR) is proving to be a beneficial strategy to sensitize tumor cells to treatment. In this review, we will discuss how recent progress in the availability of the DDR kinase inhibitors will be key for future therapy development. Further, we will examine the principal existing DDR inhibitors, with special focus on those currently in use for GBM clinical trials.

Keywords: DNA damage response; glioblastoma; DDR inhibitors

1. Introduction

The DNA damage response (DDR) is a collective term that gathers all the mechanisms that detect DNA damages, signal them and either promote their repair or trigger cell death pathways [1,2]. It has evolved as a protective mechanism to maintain our genetic information unchanged between generations, however, in a cancer therapy context, the DDR can be considered as a negative feature [3]. Indeed, under physiological conditions, the DDR protects our genome by removing errors and avoiding the insurgence of mutations. On the other hand, in tumors treated with DNA damaging agents, efficient DNA repair systems become the major cause for treatment failure [4].

Signalling pathways regulated by the DDR are numerous and partially overlap [3]. This orchestra is responsible for processing the two main types of DNA lesions: single-strand breaks (SSBs) and double-strand breaks (DSBs) [4]. At the center of DNA damage signalling, in response to DSBs, are the phosphoinositide 3-kinase-related kinases (PIKK) ATM, ATR and DNA-PK [5]. Activation of ATM/ATR/DNA-PK by DNA damage in turn results in phosphorylation of several substrates that control various pathways involved in DNA repair, checkpoint activation, apoptosis and transcription regulation. For example, ATM and ATR activate the checkpoint kinases Chk1 and Chk2 which then phosphorylate and inactivate Cdc25 and regulate cell cycle progression [5]. Instead, SSBs can result from endogenous oxidative damage, defective activity of cellular enzymes or erroneous incorporation of ribonucleotides in DNA [3]. Repair can occur through base excision repair (BER), involving poly (ADP-ribose) polymerase-1 and 2 (PARP1 and PARP2). PARP1 and PARP2 are crucial proteins for BER and act as sensors of SSBs promoting the recruitment and activation of critical downstream SSB repair effectors [3].
Accumulating evidence demonstrated that aberrant activation of DDR proteins (ATM, ATR, DNA-PK, Chk1, Chk2 and PARP) in cancer is strongly correlated with resistance to genotoxic anti-tumor therapeutics of cancer cells [3]. For this reason, DDR inhibitors are promising candidates in cancer treatment (Figure 1). More interestingly, DDR inhibitors have the potential to elicit synthetic lethal effects. Cancer cells with defects in one DDR pathway often depend on other pathways for their survival, and targeting these pathways of reliance can be exploited to cause selective cancer cell death [2].

In this review, we will briefly discuss the DNA damage response and how it can drive therapy resistance, with particular attention to glioblastoma (GBM). The DNA repair systems have already been extensively described elsewhere [1,5]. Here, we will mainly focus our attention on the three apical kinases of the DNA damage response, namely ataxia-telangiectasia-mutated (ATM), ataxia-telangiectasia- and Rad3-related (ATR) and DNA-dependent protein kinase (DNA-PK), and analyze how they can contribute to therapy resistance. Further, we will enumerate the major inhibitors that have been developed for each kinase, with special attention to those that have entered clinical trials that include GBM patients (see Table 1).

Finally, we will dedicate a paragraph to PARP inhibitors, which were the firsts DDR inhibitors (DDRi) to be developed and are currently the most studied either alone or in combination with other forms of treatment.

Figure 1. Treatment of cancerous cells with the standard combination of ionizing radiation (IR) and temozolomide (TMZ) causes DNA damage and subsequent activation of the DNA damage response (DDR) kinases (i.e., ATM, ATR and DNA-PK). Over-activation of such proteins is frequent in cancers and is responsible for therapy resistance. Addition of a DDR inhibitor to standard therapy helps reduce DNA repair rate and increases the mortality of tumor cells. Inhibitors shown in the graphic are currently been tested for glioblastoma multiforme (GBM) treatment. IR, ionizing radiation; TMZ, temozolomide.

2. Glioblastoma Multiforme

Glioblastoma multiforme is the most aggressive of brain tumors. Despite early treatment, patients’ survival remains dismal, with an approximate life expectancy of 14 months [6]. Standard care after surgery consists of a combinatory therapy of ionizing radiations (IR) and temozolomide (TMZ). Both IR and TMZ act by damaging the DNA. IRs directly cause irreversible clustered DNA damage, generating interstrand crosslinks (ICL), single- or double-strand breaks leading to cell death [7]; on the other
hand, TMZ has a more intricate mechanism of action. It can produce up to 12 different lesions, the most frequent being: N7-methylguanine (N7MeG) (80–85%), N3-methyladenine (N3MeA) or N3-methylguanine (N3MeG) (8–20%). Despite their frequency, these lesions are not by far as lethal as the minor O6-methylguanine (O6MeG) lesion (8%) [8]. The formation of this adduct causes the guanine to mispair with thymine, therefore activating the mismatch repair system (MMR). The MMR removes the incorrect thymine creating a gap. When the polymerase tries to seal the gap, it misreads the O6MeG once again and pairs it with a new thymine, thereby initiating a so-called “futile repair cycle” [9,10]. After the second round of repair, replication forks stall and collapse, generating a double-strand break (DSB) and activating proteins of the DDR [11]. An alternative line of treatment is represented by chloroethylating nitrosoureas (CNUs), which act in a similar way producing 06-chloroethylguanine (O6-ClEtG) lesions [12].

Developing resistance to radiation and chemotherapy is a major clinical issue: a great part of resistance is caused by GBM’s enhanced activity of DNA repair systems that render DNA damaging treatments ineffective [13].

Developing resistance to radiation and chemotherapy is a major clinical issue: glioblastoma is a highly radio- and chemo-resistant tumor. Radio-resistance and chemo-resistance can be defined as the capacity of cancer cells to resist respectively to ionizing radiations or chemotherapeutic drugs. These characteristics render GBM a very difficult tumor to treat [3]. Although the molecular basis for its innate resistance has not been fully elucidated, a great part of it has been linked to the presence of cancer stem cells which are responsible for cancer initiation and recurrence and are characterized by the aberrant functionality of the DNA repair machinery. Indeed, GBM’s ability to resist DNA insults is directly attributable to its innate upregulation of DNA repair pathways which render treatments ineffective [13].

3. The DNA Damage Response in Mediating Resistance in Glioblastoma

Cells are constantly exposed to either exogenous or endogenous stresses that can lead to DNA damage and threaten the genomic integrity of the cell. As a form of protection, mammals have evolved several types of DNA repair systems, each specific for a precise type of damage [1].

Broadly, these repair systems can be divided in two groups: those repairing SSBs and those handling DSBs. Common cancer therapy includes radiation and chemotherapy, which trigger the formation of both single-strand and double-strand breaks, therefore stimulating the response of both types of repair mechanisms.

3.1. Single Strand Break Repair Systems

Single-strand break (SSB) repair systems comprehend base excision repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR). All these systems operate by firstly recognizing and removing the damaged portion of the DNA. They then use the other strand as a template to synthetize a new correct sequence and seal the gap [1].

SSB repair systems are significantly activated after chemotherapy. As discussed above, administration of alkylating or chloroethylating drugs results in the formation of DNA adducts [8,12] that, upon detection by the repair machinery, can be repaired by either BER or NER accordingly to the type of damage. In a therapeutic context, the hope lies in the incapacity of the system to repair the induced lesions. Therefore, the activation of early repair systems such as BER and NER jeopardizes the attempt to turn the DNA adducts into greater forms of damage and lead cancerous cells to death [14].

It is otherwise important to specify that, while as a general rule, increased activation of DNA repair systems is counterproductive for standard cancer therapy, each type of treatment and repair mechanism must be considered individually. In fact, when discussing TMZ treatment, activation of BER and NER systems is not desirable. On the contrary, an operating MMR is instead required: with no active MMR, no “futile repair cycle” occurs and the DNA adducts are never converted into DSBs, which are ultimately what endangers the tumor [9,10].
The role of the MMR system in promoting TMZ sensitivity has also emerged in a recent CRISPR-Cas9 screening aimed at identifying genes that mediate TMZ resistance [15]. The screening was performed on patient-derived glioblastoma stem cells (GSCs) treated with high doses of TMZ. The results highlighted that three weeks after treatment, resistant cells displayed an enrichment of four genes involved in the MMR (MLH1, MSH2, MSH6 and PMS2) [15]. Of note, in recurrent GBM, a significant decrease in the MSH2, MSH6 and PMS2 protein expression level was reported [16], and reduction in MLH1 and PMS2 correlated with TMZ resistance [17].

3.2. Double Strand Break Repair Systems

When the damage is more extended and comprises both strands, the repair mechanisms are more complex. This is largely because when DNA information is missing from both strands, the polymerase has no template to copy to generate the new strand [1].

The two repair systems involved in double-strand break (DSB) repair are homologous recombination (HR) and non-homologous end-joining (NHEJ). The first one can only work if cells are damaged whilst in their late S/G2 phase of the cell cycle. This is because only during these phases the DNA has been replicated and each cell disposes of two copies of each DNA strand. Therefore, the HR enables the polymerase to use the sister chromatid as a template to synthetize the repaired strand [18,19].

When cells are damaged in different phases of the cell cycle and lack a second copy of the DNA, the NHEJ is called into action. The heterodimer KU 70/80 binds the DSB and recruits the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). With no template to copy from, the NHEJ acts by joining the two ends of the DSB. This system is then able to repair the DSB but does not restore DNA to its original state before the damage [20].

The CRISPR-Cas9 screening cited above also identified genes involved with DSB repair mechanisms as essential for TMZ-resistance [15]. The spotted genes (e.g., MCM8 and MCM9) are connected to Fanconi anemia/interstrand crosslink and homologous recombination. In fact, knockout of MCM8 or MCM9 significantly increased TMZ sensitivity in GSCs, despite having no effect on non-tumor neuronal stem cells (NSCs) [15].

4. Temozolomide Treatment and Cell Death

The DNA damage response exerts its function first of all by regulating the cell cycle and at a second stage by triggering either repair or death signalling pathways. Among the first proteins to be recruited to the DSB, ATM and ATR kinases are key in sensing the damage and initiating a downstream signalling cascade [12,21].

As soon as DNA damage is detected, the cell cycle is arrested. One of the first goals of the ATR/ATM signalling cascade is in fact to activate checkpoint kinases 1 and 2 (Chk1 and Chk2) and slow down the cell cycle [1]. Once the cycle has been arrested, the cell attempts to repair the damage. However, if such damage is too extended, the prolonged activation of the DDR kinases spurs either apoptotic or necrotic death pathways [22].

**TMZ and CNUs Affect Cell Cycle and Death**

TMZ creates lesions that cause replication forks to stall, activating in the first place the ATR-Chk1 axis. Only at a later stage is the ATM-Chk2 axis triggered, probably due to secondary effects caused by DSBs at collapsed replication forks [23,24]. It has been demonstrated that TMZ preferentially induces cells to arrest in the G2/M phase of the cell cycle: a recent work showed that 48h post-TMZ, GBM cells (i.e., T98G) are preferentially retained in this phase [25]. Similarly, another study had previously evidenced an increase in the percentage of G2/M cells upon TMZ treatment [26]. This G2/M arrest appears to be independent of p53 status as TMZ administration was shown to spur G2/M arrest both in p53-proficient (i.e., U87MG) and p53-deficient (i.e., E6-transfected U87MG and LN-Z308) GBM cell
lines. The difference between p53-proficient and p53-deficient cells lays in the duration of this G2/M arrest, which is prolonged for p53-proficient cells [26].

Otherwise, it is also known that TMZ-induced ATM/ATR activation leads to p53 phosphorylation on serine 15 and 20, arresting the cell cycle in G1/S, thereby promoting transcription of pro-survival genes [27]. When damage is too extensive to be repaired, TMZ also promotes p53 phosphorylation on serine 46 which induces transcription of pro-apoptotic genes as FAS, BAK, BAX, PUMA and PTEN, preferentially leading to apoptotic cell death [28]. The G1/S arrested population is the one that undergoes apoptotic death, while the cells arrested in G2/M are more likely to become senescent if they have the wild-type p53 [25].

For both alkylating and chloroethylating drugs, p53 status is also key in deciding which death pathway to trigger. Gliomas expressing the wild-type p53 trigger the extrinsic pathway of apoptosis upon TMZ and the intrinsic pathway upon CNUs administration [29]. On the other hand, non-functioning p53 mainly results in the activation of the apoptotic intrinsic pathway upon TMZ and necrosis upon CNU administration [28].

5. Inhibition of DDR Kinases to Overcome Therapy Resistance in GBM

In the next paragraphs, we will consider the role of apical DDR kinases in repairing DNA damage and explore existing inhibitors that have been developed for these proteins. For each kinase, we will examine on-going or recently concluded clinical trials to underline the importance of DDR inhibitors in cancer therapy, especially for tumors that have a naturally hyperactive DDR, such as GBM.

5.1. ATM

ATM is a serine/threonine kinase belonging to the phosphatidylinositol-3 kinase-like kinase (PIKK) family. It is activated by several stimuli, including DNA DSBs, hypoxia and reactive oxygen species (ROS) and plays a dual role in cancer [30]. When both strands of the DNA are damaged, the sensor complex MRN (Mre11-Rad50-Nbs1) is engaged at the site of the damage. This in turn can recruit ATM, which becomes activated through an auto-phosphorylation process thereby initiating a signalling cascade. Among its main targets, there are Chk2 and p53. The activation of this signalling cascade leads to cell cycle arrest preferentially in the G1/S checkpoint [31], but also in the G2/M checkpoint [32] and consequently to either repair of the damage or initiation of death pathways.

ATM depletion results in an autosomal recessive disorder known as ataxia-telangiectasia which displays increased sensitivity to radiation. Knowledge of this suggested that inhibitors targeting ATM (ATMi) could be used as radio- or chemo-sensitizers, electing them among the firsts DDR inhibitors to be developed, starting from the small molecule ATP-analogue KU55933 [33]. This first-generation drug was a selective ATM inhibitor but lacked several fundamental drug attributes, such as good aqueous solubility and bioavailability and it was therefore soon substituted by its derivative KU60019 [34] and by CP466722 [35]. Second-generation drugs, such as AZ32, brought considerable improvement to drugs’ availability and to their capacity to cross the brain–blood barrier (BBB) [36].

Pre-clinical studies have highlighted a promising effect for ATMi ameliorating patient’s response to radiations (or radiomimetic drugs) and topoisomerase I/II drugs (e.g., camptothecin, etoposide, doxorubicin) [33–36].

High-throughput screenings are also proving useful in the constant search for new molecules that could inhibit ATM. A cell-based screening mechanism, employing the in-cell Western (ICW) immunoassay, was used to identify two new molecules that could potentially act as ATM inhibitors: SJ573017, a potent Polo-like kinase 1 (PLK1) and 3 (PLK3), and SJ573226, a GSK-3 kinase inhibitor [37].

More recently, ATMi have entered Phase-I clinical trials either as monotherapy or in combination with other forms of treatment. As far as GBM is concerned, the ATM inhibitor AZD1390 was specifically optimized to cross the BBB and has a good central nervous system (CNS) availability [38]. Its toxicity is currently being evaluated in a clinical trial combining AZD1390 and IR (see Table 1 CT-NCT03423628).
ATM plays a key role in DSB repair by homologous recombination (HR) as it triggers the formation of single-strand DNA overhangs that are key for HR initiation. Moreover, ATM loss is frequently reported in cancers and has been shown to cause a “mild” HR deficiency [39]. Synthetic lethality between ATM and ATR was revealed in several studies and spurred the usage of ATMi to sensitize HR-proficient cells to treatment [40].

As far as the role of p53 is concerned, contrasting studies have been published regarding the significance of p53 status for ATM inhibitor-induced toxicity. For example, studies conducted on human colorectal cancer cell lines showed p53 status to be inconsequential for ATMi KU59403 radio-sensitizing effect [41]. On the other hand, a study using GBM cell lines pointed out that KU60019 would render mutant p53 cells more sensitive to therapy than the correspondent p53-WT cell line [42]. Whether differences can be imputable on the different types of inhibitors used, the different ways in which sensitivity is determined or on the tumor type remains to be clarified.

The main target of ATM, Chk2, has also been under investigation for the generation of inhibitor molecules, but studies have so far only reached the pre-clinical stage, at least for GBM: PV1019 [43] and CCT241533 [44] were used in combination with IR, bleomycin or the PARP inhibitor olaparib in GBM cell lines. The least selective inhibitor AZD7762 which targets both Chk2 and Chk1 reached a Phase-I clinical trial for GBM, but this had to be terminated early due to cardiotoxicity issues [45].

5.2. ATR

ATR is a serine/threonine kinase belonging to the PIKK family but, differently to ATM, it responds to single-strand DNA (ssDNA). Single-strand DNA is commonly generated when replication forks stall and collapse or during the processing of DSB sites [46]. Replication protein A (RPA) coats ssDNA to stabilize it and avoid the formation of destructive secondary structures. ATR works in couple with ATR-interacting protein (ATRIP), which is used to recruit ATR to RPA-coated ssDNA [46]. Once recruited to the site of the damage, regulatory complexes such as 9-1-1 (Rad9-HUS1-Rad1) stimulate ATR and drive its activation. Its main target is Chk1 which arrests the cell cycle in the intra-S or the G2/M phase [46].

The first ATR inhibitor (ATRi) to be developed, VE-821, was a competitive ATP-analogue that specifically inhibited ATR [47].

Both VE-821 [48] and its structural analogue AZD6738 [49] were used in pre-clinical trials on GBM cells and stem cells as monotherapy or in combination with cisplatin. Second-generation drugs VX-970 [50,51], BAY1895344 [52] and the AZ20 derivative AZD6738 [49,53] acquired ameliorated selectivity and oral availability and were the first ATRi to enter clinical trials. There are currently several undergoing Phase-I/II clinical trials examining ATRi: AZD6738 is so far the only inhibitor suitable for glioma patients thanks to improved BBB-permeability [53].

As discussed above for ATMi, also ATRi are able to increase toxicity more powerfully in cancer cells lacking ATM or that display a mutated form of p53 [54–56]. Coherently, ATM deficiency is one of the most advantageous biomarkers used for patient’s selection in clinical trials employing ATRi [40,49,57].

It is otherwise interesting to note that ATRi have also been found to synergize with Chk1 inhibitors, increasing their toxicity, although the reason for this is still poorly understood [58].

Chk1 inhibitors as SRA737 [59] and LY2606368 [60] are being evaluated in Phase I/II clinical trials, not involving GBM patients so far. Their BBB-permeability is still unclear and under investigation, but a Phase-I clinical trial for LY2606368 including medulloblastoma patients may lead the way for future studies in other brain tumors (see Table 1, CT-NCT04023669).

Synthetic lethality of ATRi or Chk1 has been proven also together with Wee1 inhibitors [61,62]. Wee1 is a kinase activated by Chk1 that inhibits cyclin-dependent kinase 1 (CDK1), thereby preventing mitotic entry [63].

Loss of the phosphatase CDC25A has been identified as a major cause for resistance to ATR inhibitors [64]. CDC25A loss causes cells to arrest before they undergo mitosis, thereby reducing
the impact of DNA-damaging agents. A way around this form of resistance is represented by the concomitant use of Wee1 inhibitors. The only Wee1 inhibitor available so far is MK1775 and is currently under Phase-I evaluation. It forces mitotic entry before replication has been completed resulting in abnormal mitoses and cell death [65,66]. It has a good BBB-permeability and is being tested in GBM patients treated with IR and TMZ [66–68].

5.3. DNA-PK

DNA-PK is once again a serine/threonine kinase belonging to the PIKK family. It is composed of the DNA binding heterodimer KU70/KU80 and the catalytic subunit called DNA-PKcs. It is a key protein in the non-homologous end-joining repair system, which as mentioned above, is required for the repair of DSBs that occur before DNA duplication [20].

Currently there are two DNA-PK inhibitors being tested in clinical trials: M3814 [69,70] is being tested in a Phase-I clinical trial for advanced solid tumors and leukemia patients that have ATM deficiency. Indeed, DNA-PK inhibitors have previously been demonstrated to increase lethality in cancers with ATM loss [71,72]. CC-115 is a recent compound which is able to cross the BBB and whose toxicity and efficacy are being evaluated in GBM patients, combined with IR and TMZ treatment [73].

5.4. PARP

Poly (ADP-ribose) polymerases (PARPs) are a family of 18 proteins united by their ability to transfer ADP-ribose to target proteins. PARP1 is the first and best studied protein of the family and shares 69% homology with PARP2. Both PARP1 and PARP2 are best known for their role in DNA repair mechanisms [74]. PARP proteins respond to SSBs and are involved in the base excision repair (BER) pathway, being part of the BER complex together with DNA ligase II, DNA polymerase β and XRCC1 [75]. Chemotherapeutic agents such as alkylating or chloroethylating agents typically induce a form of DNA damage that activates BER [3].

There is evidence for PARP upregulation in several types of cancers: hepatocellular carcinoma [76], breast cancer and ovarian cancer [77]. As far as GBM is concerned, PARP-1 was found to be more expressed in GBM biopsies than in healthy donor tissues [13,78]. Altogether, these findings suggest that inhibition of PARP activity may be beneficial for tumor treatment. In fact, PARP-deficient mice were found to be more sensitive to radiation and DNA-damaging agents [79].

Tumors that display impaired homologous recombination (HR) capacity, such as BRCA1-BRCA2-mutated tumors, were found to be strongly dependent on PARP-1 activity and therefore possibly more sensitive to its inhibition [80]. This is the reason why the first PARP inhibitors were specifically developed for ovarian or breast cancers displaying BRCA1/2 defects [81,82].

ARIEL2 and ARIEL3 were double-blinded Phase-II and Phase-III clinical trials evaluating the effect of the PARP inhibitor Rucaparib as monotherapy for ovarian cancer with HR deficiency [83]. Pre-clinical studies have focused on trying to extend Rucaparib use to GBM treatment in combination with TMZ. Despite having obtained promising results on GBM cultures, Rucaparib failed to improve TMZ sensitivity in orthotopic models, due to extremely poor CNS permeability [84]. On the other hand, Niraparib [85] and Veliparib [86] both showed good BBB-penetration and were approved for Phase-I/II clinical trials on GBM patients.

The GBM standard treatment drug temozolomide induces toxicity mainly through O6-MeG lesions because N3-MeA and N7-MeG lesions are easily repaired by BER [8]. Since PARP inhibitors are known to affect the BER system, they were thought to be potentially good TMZ sensitizers, by restoring the lethality of N3-MeA and N7-MeG adducts that make up 80% of TMZ-induced lesions. Whether TMZ sensitization by PARP inhibitors is due to their effect on the BER repair system or not is under investigation; knock-down of other BER proteins failed to further increase PARP-mediated TMZ sensitization, which was instead enhanced by knock-down of HR key proteins such as BRCA1 or Rad51 [87]. Another recent study pointed out a BER independent role for PARPi Veliparib and Olaparib in restoring TMZ sensitivity in cells that were resistant due to MMR deficiency [88].
At last, we discuss the PARP inhibitor Olaparib [89]. Olaparib is undergoing a Phase-I clinical trial for GBM in combination with radiation, TMZ and bevacizumab. Despite no evidence for Olaparib as a CNS available drug, it is being tested for brain tumors as well, as recent evidence has highlighted that many GBM patients show compromised integrity of the BBB and that in such cases, Olaparib may be successfully delivered to the tumor [90].

Many pre-clinical trials involving PARP inhibitors and TMZ have failed due to the high haematological toxicity induced by the combination of these drugs [91]. A solution could be presented by the Phase-I study PARADIGM-2 [92], which is studying dose-dependent toxicity in GBM patients that have been divided according to their MGMT expression. MGMT is a demethylase that removes TMZ-induced alkyl-adducts rendering TMZ treatment ineffective [93]. PARADIGM-2 patients that have methylated and poorly expressed MGMT are administered Olaparib plus radiation and TMZ, while TMZ-resistant patients with high levels of MGMT are treated with Olaparib plus a higher dose of radiation only [92].

6. Conclusions

Over recent years, the DDR has gained increasing importance in cancer treatment. Better understanding of the mechanisms regulating the DDR in cancer have helped clarify the role of the major DDR kinases in response to chemotherapy and radiation and have encouraged the development of DDRi as potential treatments. GBM is a multifaceted tumor that owes much of its incurability to the upregulation of DNA repair pathways that contrast therapy-induced DNA damage. All in all, when evaluating GBM treatment, many factors have to be kept in mind: HR efficacy, BER activity, MGMT status and drug BBB-penetrating ability being only part of the picture. What is certain is that the recent advances in DNA sequencing techniques and improvement of DDR inhibitors will enable a personalized form of treatment for patients, which may represent a valuable solution for a complex and variable tumor such as GBM.
Table 1. Summarizes the main inhibitors that target proteins of the DNA damage response. For each compound, existing clinical trials have been noted, focusing on those involving GBM patients where possible. Further, pharmacologically relevant characteristics such as the drug’s availability and blood–brain barrier (BBB) permeability have been highlighted.

| Kinase | Inhibitor | Clinical Trial Phase | End Date | Drug Combinatory Strategy | Characteristics | BBB Permeability | Tumors/Cell Lines | Reference |
|--------|-----------|----------------------|----------|---------------------------|-----------------|-----------------|------------------|-----------|
|        |           |                      |          |                           |                 |                 |                   |           |
| ATM    | ATM       |                      |          |                           |                 |                 |                   |           |
|        | KU55933   | Pre-clinical         | -        | +IR +etoposide phosphate  | Poor aqueous solubility and poor bioavailability | no              | Human cervical cancer (HeLa), Human osteosarcoma (U2OS) | [33,94] |
|        | KU60019   | Pre-clinical         | -        | -                         | Poor aqueous solubility and poor bioavailability | no              | Human glioma (U87, U1241) | [34]    |
|        | CP466722  | Pre-clinical         | -        | +temozolomide             | Improved aqueous solubility and bioavailability | no              | Human breast cancer cell line (MCF7), fibroblasts (HFF), A-T cells, GBM12 glioblastoma xenograft cell lines | [35]    |
|        | KU59403   | Pre-clinical         | -        | +irinotecan +etoposide phosphate | Improved aqueous solubility and bioavailability | no              | Human colon cancer (HCT116, SW620), Human osteosarcoma (U2OS), Human breast cancer (MDA-MB-231) | [41]    |
|        | AZ32      | Pre-clinical         | -        | +IR                       | Good bioavailability | yes (poor)      | Human glioma (U87, LN18, T98G, . . . , A172) | [36]    |
|        | AZD30156  | Phase-I              | 30 April 2020 | +olaparib +irinotecan | - | yes (poor) | Various metastatic solid tumours (including gastric adenocarcinoma, colorectal cancer) | [95] |
|        | AZD1390   | Phase-I              | 05 April 2022 | +IR                       | Good bioavailability | yes | Primary and recurrent glioblastoma multiforme | [38] |
| ATR    | VE-821    | Pre-clinical         | -        | +cisplatin                | - | yes (poor) | Hamster ovarian cells (AA8), hamster lung fibroblasts (V79), human glioblastoma multiforme (M0397) | [47] |
|        | NU-6027   | Pre-clinical         | -        | +cisplatin +PARP +hydroxyurea | - | unclear | Breast cancer, pancreatic cancer, ovarian cancer | [96] |
|        | AZ20      | Pre-clinical         | -        | monotherapy               | Poor aqueous solubility | yes (poor) | Colorectal adenocarcinoma cell line (HT29), glioblastoma CSCs | [55,97] |
Table 1. Cont.

| Kinase | Inhibitor | Clinical Trial Phase | End Date | Drug Combinatory Strategy | Characteristics | BBB Permeability | Tumors/Cell Lines | Reference |
|--------|-----------|----------------------|----------|---------------------------|-----------------|-----------------|------------------|-----------|
| ATR    | VX-970    | Phase-I NCT02157792  | 11 March 2020, 30 April 2025 | monotherapy +cisplatin | -               | unclear         | Advanced solid tumors | [50,51]  |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
|        | BAY1895344| Phase-I NCT03188965  | 25 March 2022 | monotherapy              | -               | unclear         | Solid cancers and lymphomas | [52]    |
|        | AZD6738  | Phase-II NCT03682289 | 19 March 2023 | +olaparib                | Good oral bioavailability | yes (good) | Renal and pancreatic carcinoma, glioma initiating cells | [49,53] |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
| DNAPK  | M3814    | Phase-I NCT02316197  | 19 December 2020 | monotherapy +IR +cisplatin +doxorubicin | Orally bioavailable | unclear | CLL and solid tumors | [69,70] |
|        |          | NCT02516813 clinicaltrials.gov | |                           |                 |                 |                   |           |
|        | CC-115   | Phase-I NCT02977780  | May 2022 | +neratinib +temozolomide | -               | yes (good)      | Glioblastoma multiforme | [73]    |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
| Chk2   | PV1019   | Pre-clinical         | -        | +IR +topotecan            | Good bioavailability | yes (good) | Human breast cancer (MCF7), Human ovarian cancer (OVCAR-3,4,5,8), Human glioblastoma (U251) | [43]    |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
|        | CCT241533| Pre-clinical         | -        | +bleomycin +olaparib +IR  | Good bioavailability | yes (good) | Human colorectal cancer (HT-29), human breast cancer (MCF7), human glioblastoma (U87MG), human ovarian cancer line (OVCAR-3,5) | [44]    |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
| Chk2/Chk1 | AZD7762  | Phase-I NCT00473616  | February 2011, terminated due to cardiotoxicity | +irinotecan | -               | unclear         | Solid advanced tumors, glioblastoma primary isolates (pre-clinical) | [45]    |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
| Chk1   | LY2606368| Phase-I NCT04023669  | June 2026 | +gemcitabine +cyclophosphamide | Good oral bioavailability | unclear | Advanced solid tumors, medulloblastoma | [60]    |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
|        | SRA737   | Phase-I/II NCT02797964 NCT02797977 clinicaltrials.gov | 28 October 2019 | monotherapy +cisplatin +gemcitabine | Good oral bioavailability | unclear | Advanced solid tumors, Non-Hodgkin’s lymphoma | [59]    |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
| Wee1   | MK-1775  | Phase-I NCT02207010 NCT01849146 clinicaltrials.gov | May 2018, 28 September 2020 | monotherapy +IR +temozolomide | Good oral bioavailability | yes (good) | Recurrent glioblastoma, Glioblastoma xenografts, Human glioblastoma cell line (U251, U87MG, T98G) | [66-68] |
|        |          | clinicaltrials.gov   |          |                           |                 |                 |                   |           |
| Kinase | Inhibitor | Clinical Trial Phase | Tumors/Cell Lines | Drug Combinatory Strategy | Characteristics | Reference |
|--------|-----------|----------------------|------------------|---------------------------|----------------|-----------|
| Rucaparib | Phase II NCT01891344 Phase III NCT01968213 Phase III NCT01968213 clinicaltrials.gov | 31 October 2021 June 2020 | monotherapy | Good oral availability | yes (poor) | Ovarian cancer, Epithelial ovarian cancer, Fallopian tube cancer [83,84,98,99] |
| Niraparib | Phase I NCT01294735 Phase II NCT03307785 | May 2012 February 2020 | monotherapy + temozolomide + bevacumab + carboplatin | Good bioavailability | yes (good) | Melanoma, Glioblastoma Multiforme, Metastatic solid tumors [85] |
| Veliparib | Phase I NCT01514201 Phase II NCT035581292 Phase III NCT02152982 | 28 March 2018, 29 October 2019, 14 January 2021 | + IR + temozolomide | Good oral bioavailability | yes (good) | Newly diagnosed Glioblastoma and glioma [86] |
| Olaparib | Phase II NCT03233204 Phase II NCT02974621 Phase III NCT03212742 | 30 September 2024, 31 May 2020, 31 July 2020, 30 June 2022 | monotherapy + bevacizumab + IR + temozolomide | Good oral bioavailability | yes (poor) | Non-hodgkin lymphoma, Advanced solid tumours, Glioma [89,90] |
Author Contributions: Conceptualization, A.F., V.S. and D.B.; writing—original draft preparation, A.F.; writing—review and editing, A.F., V.S. and D.B.; supervision, D.B.; funding acquisition, D.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Associazione Italiana per la Ricerca sul Cancro (AIRC)-IG2016-n.19069, MIUR-JP1-HDHL-NUTRICOG-MiTyrAge, PRIN_2015LZE994_005, and the Italian Ministry of Health, RF-2016-02362022 to D.B. A.F. is funded by the PhD programme in Molecular and Cellular Biology, University of Rome Tor Vergata. The study was supported for V.S. by a research grant from Italian Ministry of Health RF-2016-02363460.

Acknowledgments: We acknowledge all our laboratory members for critical reading of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| 9-1-1        | Rad9-HUS1-Rad1 |
| ATM          | Ataxia-telangiectasia-mutated |
| ATR          | Ataxia-telangiectasia- and Rad3-related |
| BAK          | Bcl2 antagonist/killer |
| BAX          | Bcl2 associated X protein |
| BBB          | Blood–brain barrier |
| BRCA1        | Breast cancer 1 |
| CDC25A       | Cell division cycle 25A |
| CDK1         | Cyclin dependent kinase 1 |
| CHK1         | Checkpoint kinase 1 |
| CHK2         | Checkpoint kinase 2 |
| CNU          | Chloroethylating nitrosoureas |
| DDR          | DNA damage response |
| DDRi         | DNA damage response inhibitors |
| DNA-PK       | DNA-dependent protein kinase |
| DSb          | Double-strand break |
| GBM          | Glioblastoma multiforme |
| GSC          | Glioblastoma stem cell |
| HR           | Homologous recombination |
| IR           | Ionizing radiation |
| MCM8         | Minichromosome maintenance 8 |
| MCM9         | Minichromosome maintenance 9 |
| MGMT         | O-6-Methylguanine DNA-methyltransferase |
| MLH1         | MutL homologue 1 |
| MMR          | Mismatch repair |
| MRN          | Mre11-Rad50-Nbs1 |
| MSH2         | MutS homologue 2 |
| MSH6         | MutS homologue 6 |
| NSC          | Neural stem cell |
| NHEJ         | Non-homologous end-joining |
| PARP         | Poly-ADP-ribose polymerase |
| PIKK         | Phosphatidylinositol 3-kinase related kinase |
| PMS2         | PMS1 homolog 2 |
| PTEN         | Phosphatase and tensin homologue |
| PUMA         | P53 upregulated modulator of apoptosis |
| ROS          | Reactive oxygen species |
| SSb          | Single-strand break |
| TMZ          | Temozolomide |
| XRCC1        | X-ray repair cross-complementing 1 |

References

1. Jackson, S.P.; Bartek, J. The DNA-damage response in human biology and disease. *Nature* 2009, 461, 1071–1078. [CrossRef] [PubMed]
2. Li, Z.; Pearlman, A.H.; Hsieh, P. DNA mismatch repair and the DNA damage response. *DNA Repair (Amst)* 2016, 38, 94–101. [CrossRef] [PubMed]
3. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. *Nat. Rev. Cancer* 2008, 8, 193–204. [CrossRef] [PubMed]
4. Kaina, B.; Christmann, M. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. *DNA Repair (Amst)* 2019, 78, 128–141. [CrossRef]

5. Blackford, A.N.; Jackson, S.P. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. *Mol. Cell* 2017, 66, 801–817. [CrossRef]

6. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 2005, 352, 987–996. [CrossRef]

7. Behjati, S.; Gundem, G.; Wedge, D.C.; Roberts, N.D.; Tarpey, P.S.; Cooke, S.L.; Van Loo, P.; Alexandrov, L.B.; Ramakrishna, M.; Davies, H.; et al. Mutational signatures of ionizing radiation in second malignancies. *Nat. Commun.* 2016, 7, 12605. [CrossRef]

8. Zhang, J.; Stevens, M.F.; Bradshaw, T.D. Temozolomide: Mechanisms of action, repair and resistance. *Curr. Mol. Pharm.* 2012, 5, 102–114. [CrossRef]

9. Ochs, K.; Kaina, B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. *Cancer Res.* 2000, 60, 5815–5824.

10. Roos, W.P.; Kaina, B. DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis. *Cancer Lett.* 2013, 332, 237–248. [CrossRef]

11. Quiros, S.; Roos, W.P.; Kaina, B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. *Cell Cycle* 2010, 9, 168–178. [CrossRef] [PubMed]

12. Nikolova, T.; Roos, W.P.; Krämer, O.H.; Strik, H.M.; Kaina, B. Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. *Biochim. Biophys. Acta Rev. Cancer* 2017, 1868, 29–39. [CrossRef] [PubMed]

13. MacLeod, G.; Bozek, D.A.; Rajakulendran, N.; Monteiro, V.; Ahmadi, M.; Steinhart, Z.; Kushida, M.M.; Yu, H.; Coutinho, F.J.; Cavalli, F.M.G.; et al. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. *Cell Rep.* 2019, 27, 971–986.e979. [CrossRef] [PubMed]

14. Li, X.; Heyer, W.D. Homologous recombination in DNA repair and DNA damage tolerance. *Cell Res.* 2008, 18, 99–113. [CrossRef] [PubMed]

15. San Filippo, J.; Sung, P.; Klein, H. Mechanism of eukaryotic homologous recombination. *Annu. Rev. Biochem.* 2008, 77, 229–257. [CrossRef]

16. Chang, H.H.Y.; Pannunzio, N.R.; Adachi, N.; Lieber, M.R. Non-homologous DNA end joining and alternative pathways to double-strand break repair. *Nat. Rev. Mol. Cell Biol.* 2017, 18, 495–506. [CrossRef]

17. Langerak, A.; Russell, P. Regulatory networks integrating cell cycle control with DNA damage checkpoints and double-strand break repair. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 2011, 366, 3562–3571. [CrossRef] [PubMed]
23. Roos, W.P.; Nikolova, T.; Quiros, S.; Naumann, S.C.; Kiedron, O.; Zdzienicka, M.Z.; Kaina, B. Brca2/Xrc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. *DNA Repair (Amst)* 2009, 8, 72–86. [CrossRef] [PubMed]

24. Eich, M.; Roos, W.P.; Nikolova, T.; Kaina, B. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. *Mol. Cancer* 2013, 12, 2529–2540. [CrossRef]

25. Barciszewska, A.M.; Gurda, D.; Glodowicz, P.; Nowak, S.; Naskrét-Barciszewska, M.Z. A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells. *PLoS ONE* 2015, 10, e0136669. [CrossRef]

26. Hirose, Y.; Berger, M.S.; Pieper, R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. *Cancer Res.* 2001, 61, 1957–1963.

27. Matt, S.; Hofmann, T.G. The DNA damage-induced cell death response: A roadmap to kill cancer cells. *Cell Mol. Life Sci.* 2016, 73, 2829–2850. [CrossRef]

28. Roos, W.P.; Batista, L.F.; Naumann, S.C.; Wick, W.; Weller, M.; Menck, C.F.; Kaina, B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. *Oncogene* 2007, 26, 186–197. [CrossRef] [PubMed]

29. Tomicic, M.T.; Meise, R.; Aslând, D.; Berte, N.; Kitzinger, R.; Krämer, O.H.; Kaina, B.; Christmann, M. Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. *Oncotarget* 2015, 6, 33755–33768. [CrossRef]

30. Shiloh, Y.; Ziv, Y. The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. *Nat. Rev. Mol. Cell Biol.* 2014, 15, 5388–5409. [CrossRef]

31. Shiloh, Y.; Ziv, Y. The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. *Nat. Rev. Mol. Cell Biol.* 2014, 15, 197–210. [CrossRef] [PubMed]

32. Zannini, L.; Delia, D.; Buscemi, G. CHK2 kinase in the DNA damage response and beyond. *Int. J. Mol. Sci.* 2016, 17, 2529–2540. [CrossRef] [PubMed]

33. Hickson, I.; Zhao, Y.; Hussaini, I.; Frigerio, M.; Cockcroft, X.F.; Chong, W.Y.; Hummersone, M.; Rigoreau, L.; Menear, K.A.; et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. *Sci. Adv.* 2018, 4, eaat1719. [CrossRef]

34. Bakr, A.; Ong, C.; Köcher, S.; Borgmann, K.; Dornreiter, I.; Petersen, C.; Dikomey, E.; Mansour, W.Y. Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. *Nucleic Acids Res.* 2015, 43, 3154–3166. [CrossRef]

35. Kwok, M.; Davies, N.; Agathangelou, A.; Smith, E.; Oldreive, C.; Peterman, E.; Stewart, G.; Brown, J.; Lau, A.; Pratt, G.; et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. *Blood* 2016, 127, 582–595. [CrossRef]

36. Batey, M.A.; Zhao, Y.; Kyle, S.; Richardson, C.; Slade, A.; Martin, N.M.; Lau, A.; Newell, D.R.; Curtin, N.J. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. *Mol. Cancer* 2013, 12, 959–967. [CrossRef] [PubMed]
42. Biddlestone-Thorpe, L.; Saajad, M.; Rosenberg, E.; Beckta, J.M.; Valerie, N.C.; Tokarz, M.; Adams, B.R.; Wagner, A.F.; Khalil, A.; Gilfor, D.; et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin. Cancer Res. 2013, 19, 3189–3200. [CrossRef] [PubMed]

43. Jobson, A.G.; Lountos, G.T.; Lorenzi, P.L.; Llamas, J.; Connelly, J.; Cerna, D.; Tropea, J.E.; Onda, A.; Zoppoli, G.; Konadapaka, S.; et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid [4-[1-(guanidinohydrazone)-ethyl]-phenyl-amide]. J. Pharm. Exp. 2009, 331, 816–826. [CrossRef] [PubMed]

44. Anderson, V.E.; Walton, M.I.; Eve, P.D.; Boxall, K.J.; Antoni, L.; Caldwell, J.J.; Aherne, W.; Pearl, L.H.; Oliver, A.W.; Collins, I.; et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011, 71, 463–472. [CrossRef] [PubMed]

45. Tang, Y.; Dai, Y.; Grant, S.; Dent, P. Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol. 2012, 13, 379–388. [CrossRef] [PubMed]

46. Yazinski, S.A.; Zou, L. Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway. Annu. Rev. Genet. 2016, 50, 155–173. [CrossRef]

47. Charrier, J.D.; Durrant, S.; Golec, J.M.; Kay, D.P.; Knegtel, R.M.; MacCormick, S.; Mortimore, M.; O’Donnell, M.E.; Pinder, J.L.; Reaper, P.M.; et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 2011, 54, 2320–2330. [CrossRef]

48. Middleton, F.K.; Patterson, M.J.; Elstob, C.J.; Fordham, S.; Herriott, A.; Wade, M.A.; McCormick, A.; Heathcote, R.; Odedra, R.; et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J. Med. Chem. 2018, 61, 9889–9907. [CrossRef]

49. Foote, K.M.; Nissink, J.W.M.; McGuire, T.; Turner, P.; Guichard, S.; Yates, J.W.T.; Lau, A.; Blades, K.; Heathcote, D.; Odedra, R.; et al. Discovery of potent and selective inhibitors of ATR. Nat. Chem. Biol. 2009, 56, 2320–2330. [CrossRef]

50. Fokas, E.; Prevo, R.; Pollard, J.R.; Reaper, P.M.; Charlton, P.A.; Cornelissen, B.; Vallis, K.A.; Hammond, E.M.; O’Donnell, M.E.; Pinder, J.L.; Reaper, P.M.; et al. Discovery of potent and selective inhibitors of ATR. Clin. Cancer Res. 2015, 21, 4780–4785. [CrossRef]

51. Karnitz, L.M.; Zou, L. Molecular Pathways: Targeting ATR in Cancer Therapy. Clin. Cancer Res. 2015, 21, 4780–4785. [CrossRef]

52. Wengner, A.M.; Siemeister, G.; Lücking, U.; Lefranc, J.; Wortmann, L.; Lienau, P.; Bader, B.; Bömer, U.; Moosmayer, D.; Eberspächer, U.; et al. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models. Mol. Cancer 2020, 19, 26–38. [CrossRef] [PubMed]

53. Frössin, G.; Profumo, A.; Marubbi, D.; Marcello, D.; Ravetti, J.L.; Daga, A. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Radiat. Oncol. 2018, 13, 76. [CrossRef] [PubMed]

54. Boo, A.; Gopinath, T.; Long, J.M.; Charrier, J.D.; MacCormick, S.; Charlton, P.A.; Golec, J.M.; Beltt, J.; Pollard, J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7, 428–430. [CrossRef]

55. Poole, K.M.; Blades, K.; Cronin, A.; Fillery, S.; Guichard, S.S.; Hassall, L.; Hickson, I.; Jacy, X.; Hewson, P.; McGuire, T.M.; et al. Discovery of 4-[4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl]-1H-indole (AZ20): A potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. Mol. Cancer 2013, 12, 120–129. [CrossRef] [PubMed]

56. Menezes, D.L.; Holt, J.; Tang, Y.; Feng, J.; Barsanti, P.; Pan, Y.; Ghoddusi, M.; Zhang, W.; Thomas, G.; Holash, J.; et al. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol. Cancer Res. 2015, 13, 120–129. [CrossRef] [PubMed]

57. Lloyd, R.L.; Wijnhoven, P.W.G.; Ramos-Montoya, A.; Wilson, Z.; Illuzzi, G.; Falenta, K.; Jones, G.N.; James, N.; Chabbert, C.D.; Stott, J.; et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 2020. [CrossRef]
58. Sanjiv, K.; Hagenkort, A.; Calderón-Montañó, J.M.; Koolmeester, T.; Reaper, P.M.; Mortusewicz, O.; Jacques, S.A.; Kuiper, R.V.; Schultz, N.; Scobie, M.; et al. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. Cell Rep. 2016, 17, 3407–3416. [CrossRef]
59. Plummer, E.R.; Kristeleit, R.S.; Cojocaru, E.; Haris, N.; Carter, L.; Jone, R.H.; Blagden, S.P.; Evans, T.R.J.; Arkenau, H.T.; Sarker, D.; et al. A first-in-human phase I/II trial of SRA737 (a Chk1 inhibitor) in subjects with advanced cancer. J. Clin. Oncol. 2019, 37, 3094. [CrossRef]
60. Hong, D.; Infante, J.; Janku, F.; Jones, S.; Nguyen, L.M.; Burris, H.; Naing, A.; Bauer, T.M.; Piha-Paul, S.; Johnson, E.M.; et al. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J. Clin. Oncol. 2016, 34, 1764–1771. [CrossRef]
61. Bukhari, A.B.; Lewis, C.W.; Pearce, J.J.; Luong, D.; Chan, G.K.; Gamper, A.M. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis. J. Clin. Investig. 2019, 129, 1329–1344. [CrossRef] [PubMed]
62. Carrassa, L.; Chilà, R.; Lupi, M.; Ricci, F.; Celenza, C.; Mazzoletti, M.; Broggini, M.; Damia, G. Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012, 11, 2507–2517. [CrossRef] [PubMed]
63. Lee, J.; Kumagai, A.; Dunphy, W.G. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol. Biol. Cell 2001, 12, 551–563. [CrossRef] [PubMed]
64. Ruiz, S.; Mayor-Ruiz, C.; Lafarga, V.; Murga, M.; Vega-Sendino, M.; Ortega, S.; Fernandez-Capetillo, O. A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors. Mol. Cell 2016, 62, 307–313. [CrossRef] [PubMed]
65. Aarts, M.; Sharpe, R.; García-Murillas, I.; Gevensleben, H.; Hurd, M.S.; Shumway, S.D.; Toniatti, C.; Ashworth, A.; Turner, N.C. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012, 2, 524–539. [CrossRef] [PubMed]
66. Pokorny, J.L.; Calligaris, D.; Gupta, S.K.; Iyekegbe, D.O.; Mueller, D.; Bakken, K.K.; Carlson, B.L.; Schroeder, M.A.; Evans, D.L.; Lou, Z.; et al. The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma. Clin. Cancer Res. 2015, 21, 1916–1924. [CrossRef]
67. Sanai, N.; Li, J.; Boerner, J.; Stark, K.; Wu, J.; Kim, S.; Derogatis, A.; Mehta, S.; Dhruv, H.D.; Heilbrun, L.K.; et al. Phase 0 trial of AZD1775 in first-recurrence glioblastoma patients. Clin. Cancer Res. 2018, 24, 3820–3828. [CrossRef]
68. Alexander, B.; Supko, J.; Agar, N.; Ahluwalia, M.; Desai, A.; Dietrich, J.; Kaley, T.; Peereboom, D.; Takebe, N.; Desideri, S.; et al. ACTR-14. Phase I study of azd1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (idd) in patients with recurrent GBM. Neuro Oncol. 2018, 20, vi13–vi14. [CrossRef]
69. Biau, J.; Chautard, E.; Verrelle, P.; Dutreix, M. Altering DNA repair to improve radiation therapy: Specific and multiple pathway targeting. Front. Oncol. 2019, 9, 1009. [CrossRef]
70. Mohiuddin, I.S.; Kang, M.H. DNA-PK as an emerging therapeutic target in cancer. Front. Oncol. 2019, 9, 635. [CrossRef]
71. Riabinska, A.; Daheim, M.; Herter-Sprie, G.S.; Winkler, J.; Fritz, C.; Hallek, M.; Thomas, R.K.; Kreuzer, K.A.; Frenzel, L.P.; Monfared, P.; et al. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci. Transl. Med. 2013, 5, 189ra178. [CrossRef] [PubMed]
72. Kantidze, O.L.; Velichko, A.K.; Luzhin, A.V.; Petrova, N.V.; Razin, S.V. Synthetic lethal Interactions of ATM, ATR, and DNA–PKCs. Trends Cancer 2018, 4, 755–768. [CrossRef] [PubMed]
73. Munster, P.; Mita, M.; Mahipal, A.; Nemunaitis, J.; Massard, C.; Mikkelsen, T.; Cruz, C.; Paz-Ares, L.; Hidalgo, M.; Rathkopf, D.; et al. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag. Res. 2019, 11, 10463–10476. [CrossRef]
74. Amé, J.C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. Bioessays 2004, 26, 882–893. [CrossRef] [PubMed]
75. Caldecott, K.W. XRCC1 protein; Form and function. DNA Repair (Amst) 2019, 81, 102664. [CrossRef] [PubMed]
76. Nomura, F.; Yaguchi, M.; Togawa, A.; Miyazaki, M.; Isobe, K.; Miyake, M.; Noda, M.; Nakai, T. Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2000, 15, 529–535. [CrossRef]
77. Ossovskaya, V.; Koo, I.C.; Kaldjian, E.P.; Alvares, C.; Sherman, B.M. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. *Genes Cancer* 2010, 1, 812–821. [CrossRef]

78. Galia, A.; Calogero, A.E.; Condorelli, R.; Fraggetta, F.; La Corte, A.; Ridolfo, F.; Bosco, P.; Castiglione, R.; Salem, M. PARP-1 protein expression in glioblastoma multiforme. *Eur. J. Histochem.* 2012, 56, e9. [CrossRef]

79. de Murcia, J.M.; Niedergang, C.; Trucco, C.; Ricoul, M.; Dutrillaux, B.; Mark, M.; Oliver, F.J.; Masson, M.; Dierich, A.; LeMeur, M.; et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. *Proc. Natl. Acad. Sci. USA* 1997, 94, 7303–7307. [CrossRef]

80. Dziakowiec, K.N.; Gasiorowska, E.; Nowak-Markwitz, E.; Jankowska, A. PARP inhibitors: Review of mechanisms of action and BRCA1/2 mutation targeting. *Prz. Menopauzalny* 2016, 15, 215–219. [CrossRef]

81. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005, 434, 913–917. [CrossRef] [PubMed]

82. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005, 434, 917–921. [CrossRef] [PubMed]

83. Kristeleit, R.S.; Oskin, A.; Ray-Coquard, I.; Leary, A.; Balmaña, J.; Drew, Y.; Oza, A.M.; Shapira-Frommer, R.; Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase rucaparib as monotherapy in patients with platinum-sensitive, relapsed. *Int. J. Gynecol. Cancer* 2019, 29, 1396–1404. [CrossRef]

84. Parrish, K.E.; Cen, L.; Murray, J.; Calligaris, D.; Kizilbash, S.; Mittappali, R.K.; Carlson, B.L.; Schroeder, M.A.; Sludden, J.; Boddy, A.V.; et al. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. *Mol. Cancer* 2015, 14, 2735–2743. [CrossRef] [PubMed]

85. Sun, K.; Mikule, K.; Wang, Z.; Poon, G.; Vaidyanathan, A.; Smith, G.; Zhang, Z.Y.; Hanke, J.; Ramaswamy, S.; Wang, J. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. *Oncotarget* 2018, 9, 37080–37096. [CrossRef] [PubMed]

86. Gupta, S.K.; Kizilbash, S.H.; Carlson, B.L.; Mladek, A.C.; Boakye-Agyeman, F.; Bakken, K.K.; Pokorny, J.L.; Schroeder, M.A.; Decker, P.A.; Cen, L.; et al. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. *J. Natl. Cancer Inst.* 2016, 108. [CrossRef]

87. Gupta, S.K.; Smith, E.J.; Mladek, A.C.; Tian, S.; Decker, P.A.; Kizilbash, S.H.; Kitange, G.J.; Sarkaria, J.N. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. *Front. Oncol.* 2018, 8, 670. [CrossRef]

88. Higuchi, F.; Nagashima, H.; Ning, J.; Koerner, M.V.A.; Wakimoto, H.; Cahill, D.P. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. *Clin. Cancer Res.* 2020, 26, 1690–1699. [CrossRef]

89. Lesueur, P.; Lequesne, J.; Grellard, J.M.; Dugué, A.; Coquan, E.; Brachet, P.E.; Geoffrelot, J.; kao, W.; Emery, E.; Berro, D.H.; et al. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. *BMC Cancer* 2019, 19, 198. [CrossRef]

90. Hanna, C.; Kurian, K.M.; Williams, K.; Watts, C.; Jackson, A.; Carruthers, R.; Stratheen, K.; Cruickshank, G.; Dunn, L.; Erridge, S.; et al. Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: Results of the phase I OPARATIC trial. *Neuro-Oncology* 2020. [CrossRef]

91. Middleton, M.R.; Friedlander, P.; Hamid, O.; Daud, A.; Plummer, R.; Falotico, N.; Chyla, B.; Jiang, F.; McKeegan, E.; Mostafa, N.M.; et al. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. *Ann. Oncol.* 2015, 26, 2173–2179. [CrossRef] [PubMed]

92. Fulton, B.; Short, S.C.; James, A.; Nowicki, S.; McBain, C.; Jefferies, S.; Kelly, C; Stobo, J.; Morris, A.; Williamson, A.; et al. PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. *Clin. Transl. Radiat. Oncol.* 2018, 8, 12–16. [CrossRef] [PubMed]
93. Chen, X.; Zhang, M.; Gan, H.; Wang, H.; Lee, J.H.; Fang, D.; Kitange, G.J.; He, L.; Hu, Z.; Parney, I.F.; et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. *Nat. Commun.* 2018, 9, 2949. [CrossRef] [PubMed]

94. Nadkarni, A.; Shrivastav, M.; Mladek, A.C.; Schwingler, P.M.; Grogan, P.T.; Chen, J.; Sarkaria, J.N. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. *J. Neurooncol.* 2012, 110, 349–357. [CrossRef] [PubMed]

95. Riches, L.C.; Trinidad, A.G.; Hughes, G.; Jones, G.N.; Hughes, A.M.; Thomason, A.G.; Gavine, P.; Cui, A.; Ling, S.; Stott, J.; et al. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically. *Mol. Cancer* 2020, 19, 13–25. [CrossRef]

96. Peasland, A.; Wang, L.Z.; Rowling, E.; Kyle, S.; Chen, T.; Hopkins, A.; Cliby, W.A.; Sarkaria, J.; Beale, G.; Edmondson, R.; et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. *Br. J. Cancer* 2011, 105, 372–381. [CrossRef]

97. Ning, J.; Wakimoto, H.; Martuza, R.; Rabkin, S. ATR inhibitors synergize with PARP inhibitors in killing glioblastoma stem cells and treating glioblastoma. *Cancer Res.* 2017, 77, AM2017-1122.

98. Swisher, E.M.; Lin, K.K.; Oza, A.M.; Scott, C.L.; Giordano, H.; Sun, J.; Konecny, G.E.; Coleman, R.L.; Tinker, A.V.; O’Malley, D.M.; et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2017, 18, 75–87. [CrossRef]

99. Coleman, R.L.; Oza, A.M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.I.; Clamp, A.; Scambia, G.; et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017, 380, 1949–1961. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).